title: PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.
abstract: Aim: Variation at PDE3A-SLCO1C1 locus has been recently associated with the response to anti-TNF therapy in rheumatoid arthritis. We undertook the present study to determine whether PDE3A-SLCO1C1 is also associated with the response to anti-TNF therapy in psoriatic arthritis. Patients & methods: Genomic DNA was obtained from 81 psoriatic arthritis patients that had been treated with anti-TNF therapy. PDE3A-SLCO1C1 SNP rs3794271 was genotyped using Taqman realt-time PCR. The clinical response to anti-TNF therapy was measured as the change from baseline in the level of disease activity according to the DAS28 score. Results: A significant association between rs3794271 and anti-TNF response in psoriatic arthritis was found (beta = -0.71; p = 0.0036). Conclusion: PDE3A-SLCO1C1 locus is also associated with response to anti-TNF therapy in psoriatic arthritis. Original submitted 12 May 2014; Revision submitted 18 August 2014.
authors.affiliation: Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Julià
authors.forename: Jesús
authors.initials: J
authors.lastname: Rodríguez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Fernández-Sueiro
authors.forename: Jordi
authors.initials: J
authors.lastname: Gratacós
authors.forename: Rubén
authors.initials: R
authors.lastname: Queiró
authors.forename: Carlos
authors.initials: C
authors.lastname: Montilla
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Torre-Alonso
authors.forename: José Javier
authors.initials: JJ
authors.lastname: Pérez-Venegas
authors.forename: Sara
authors.initials: S
authors.lastname: Manrique-Arija
authors.forename: Santiago
authors.initials: S
authors.lastname: Muñoz-Fernández
authors.forename: Carlos
authors.initials: C
authors.lastname: González
authors.forename: Daniel
authors.initials: D
authors.lastname: Roig
authors.forename: Pedro
authors.initials: P
authors.lastname: Zarco
authors.forename: Alba
authors.initials: A
authors.lastname: Erra
authors.forename: Santos
authors.initials: S
authors.lastname: Castañeda
authors.forename: Alicia
authors.initials: A
authors.lastname: García
authors.forename: Georgina
authors.initials: G
authors.lastname: Salvador
authors.forename: César
authors.initials: C
authors.lastname: Díaz-Torne
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: Alfredo Willisch
authors.initials: AW
authors.lastname: Domínguez
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Mosquera
authors.forename: Paloma
authors.initials: P
authors.lastname: Vela
authors.forename: Jesús
authors.initials: J
authors.lastname: Tornero
authors.forename: Simón
authors.initials: S
authors.lastname: Sánchez-Fernández
authors.forename: Héctor
authors.initials: H
authors.lastname: Corominas
authors.forename: Julio
authors.initials: J
authors.lastname: Ramírez
authors.forename: Gabriela
authors.initials: G
authors.lastname: Avila
authors.forename: Arnald
authors.initials: A
authors.lastname: Alonso
authors.forename: Raül
authors.initials: R
authors.lastname: Tortosa
authors.forename: María
authors.initials: M
authors.lastname: López-Lasanta
authors.forename: Juan D
authors.initials: JD
authors.lastname: Cañete
authors.forename: Sara
authors.initials: S
authors.lastname: Marsal
keywords: anti-TNF therapy; genetic marker; psoriatic arthritis; single nucleotide polymorphism; treatment response